AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 12, 2024
Running 10 hours a week for more than 120 km (75 miles) is extreme exercise, to be sure. Yet far from pushing the body beyond its limits, a new study suggests some professional athletes are adding years to their lives with such brutal routines.
pharmaphorum
MAY 12, 2024
Pfizer reaches deal with NICE on Vyndaqel for ATTR-CM Phil.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 12, 2024
Indian pharma & nutraceutical industries see liposomal technology as a game-changer with the potential to improve drug efficacy and patient safety. This is particularly significant in the development of targeted therapies for conditions like cancer, where precise delivery of medication to specific cells or tissues is crucial.
BioSpace
MAY 12, 2024
The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could soon provide more-robust data about candidates’ efficacy and safety.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
MAY 12, 2024
The first person to receive a xenotransplant of a kidney from a pig, Rick Slayman, has died almost two months after the procedure
JAMA Internal Medicine
MAY 12, 2024
This cohort study compares 90-day mortality in patients with sepsis who received piperacillin-tazobactam vs cefepime for treatment of sepsis.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
MAY 12, 2024
The major biopharma players have promised to increase their investments in France to help boost their respective global manufacturing and R&D capabilities, with Sanofi committing more than $1 billion.
Trialfacts
MAY 12, 2024
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Centre Study Location Research Centre: UNSW School of Optometry & Vision Science Location: Rupert Myers Building (M15), Gate 14, Barker St, UNSW, Kensington NSW 2052, Australia Lead Researcher: Dr. Pauline King HREC: This study has been reviewed and approved by the UNSW Human Research Ethics Committee About the Study Has your child been diagnosed with myopia also known as shortsig
BioSpace
MAY 12, 2024
A pre-planned analysis revealed patients receiving the vibostolimab-Keytruda coformulation in a late-stage trial had a high rate of dropouts due to immune-related adverse events, Merck announced Monday.
Pharmaceutical Commerce
MAY 12, 2024
This document details the benefits of DataX, a revolutionary solution tailored for pharmaceutical manufacturers. Designed to navigate the complexities of managing serialized data for drop shipments, DataX ensures secure, compliant, and efficient data exchange.
BioSpace
MAY 12, 2024
We are in an unprecedented time in neurotherapeutics.
Pharmaceutical Commerce
MAY 12, 2024
This document outlines key strategies and testing protocols critical for optimizing EPCIS implementation, ensuring that pharmaceutical manufacturers can maintain compliance and operational efficiency.
BioSpace
MAY 12, 2024
The FDA is looking at five big decision deadlines in the coming three weeks, including two for a CAR-T therapy and another for a hepatitis B vaccine.
Drug Patent Watch
MAY 12, 2024
This chart shows the patent expirations for powder dosed drugs over the next decade. The term of drug patents varies.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
MAY 12, 2024
With its first-in-class endothelin and angiotensin II receptor antagonist Filspari, Travere Therapeutics is providing a more efficacious treatment option for the rare autoimmune disease.
Drug Patent Watch
MAY 12, 2024
Annual Drug Patent Expirations for ALIQOPA Aliqopa is a drug marketed by Bayer Healthcare and is included in one NDA. It is available from one supplier.
BioSpace
MAY 12, 2024
Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, Excision BioTherapeutics’ HIV gene editor failed to suppress viral activity.
Drug Patent Watch
MAY 12, 2024
Annual Drug Patent Expirations for ONGENTYS Ongentys is a drug marketed by Neurocrine and is included in one NDA. It is available from two suppliers.
BioSpace
MAY 12, 2024
An updated draft of the BIOSECURE Act introduced on Friday would give U.S. drug manufacturers additional leeway for existing contracts with certain Chinese “companies of concern” until 2032.
JAMA Internal Medicine
MAY 12, 2024
This case report describes a woman in her 40s with opioid use disorder receiving methadone who was admitted for extended antibiotic treatment for methicillin-resistant Staphylococcus aureus bacteremia and was subesequently diagnosed with opioid-induced adrenal insufficiency.
BioSpace
MAY 12, 2024
Amylyx’s recent decision to withdraw its ALS drug Relyvrio from the market highlights an important business decision for companies: when to continue marketing or investigating a drug that has failed a pivotal or confirmatory study.
JAMA Internal Medicine
MAY 12, 2024
This cohort study estimates the effectiveness, acceptability, and feasibility of dispensing mifepristone for medication abortion using a mail-order pharmacy.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BioSpace
MAY 12, 2024
Takeda on Monday said it is paying AC Immune $100 million upfront for an option on a Phase Ib/II Alzheimer’s disease candidate that could activate the immune system to clear amyloid beta plaques.
Expert insights. Personalized for you.
242 
Let's personalize your content